Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Depreciation and Depletion (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Depreciation and Depletion readings, the most recent being $144000.0 for Q1 2026.

  • On a quarterly basis, Depreciation and Depletion rose 311.43% to $144000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $305000.0, a 7.29% decrease, with the full-year FY2025 number at $196000.0, down 56.25% from a year prior.
  • Depreciation and Depletion hit $144000.0 in Q1 2026 for Kiniksa Pharmaceuticals International, up from $121000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $359000.0 in Q1 2022 to a low of $13000.0 in Q2 2025.
  • Median Depreciation and Depletion over the past 5 years was $154000.0 (2024), compared with a mean of $181000.0.
  • Biggest five-year swings in Depreciation and Depletion: plummeted 89.08% in 2025 and later surged 311.43% in 2026.
  • Kiniksa Pharmaceuticals International's Depreciation and Depletion stood at $294000.0 in 2022, then fell by 19.73% to $236000.0 in 2023, then plummeted by 62.71% to $88000.0 in 2024, then soared by 37.5% to $121000.0 in 2025, then rose by 19.01% to $144000.0 in 2026.
  • The last three reported values for Depreciation and Depletion were $144000.0 (Q1 2026), $121000.0 (Q4 2025), and $27000.0 (Q3 2025) per Business Quant data.